Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial - Top-Institutions - MDSpire

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • February 17, 2026

  • 3 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Multiple Sclerosis

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Clinical Trials

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Multiple Sclerosis

  • #5

    Brigham and Women’s Hospital / Harvard Medical School
    Brigham and Women’s Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

Original Source(s)

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

  • February 17, 2026

Related Content

The quality of life in Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder and their association with anxiety, depression, fatigue, and disability

Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG–seronegative NMOSD

Redefining Neuro-Ophthalmology

The eye-brain connection and the future of imaging